论文部分内容阅读
目的探讨利托君抑制宫缩时孕妇心率的变化与治疗的关系。方法回顾性分析2009年2月—2012年8月治疗的早产孕妇94例的病例资料,统计利托君使用前后患者平均心率的变化,同时根据产科并发症的情况分为四组:单纯早产组34例,前置胎盘组22例,胎膜早破组28例,双胎组10例,所有患者使用利托君治疗前后,分别统计各组的平均发病时间和平均分娩时间。结果入院时患者的平均心率为(83.43±3.89),利托君治疗后的心率平均值为(108.92±7.68),治疗前后差异有统计学意义(P<0.05),平均发病时间为(34.27±1.87)周,治疗后的平均分娩时间为(38.34±4.92)周,治疗前后差异有统计学意义(P<0.05)。结论利托君治疗后孕妇心率提高,利托君对治疗孕妇早期应用具有较好的临床效果。
Objective To investigate the relationship between the changes of pregnant women ’s heart rate and the treatment of inhibition of contractions. Methods The clinical data of 94 preterm pregnant women who were treated from February 2009 to August 2012 were retrospectively analyzed. The changes of average heart rate before and after treatment were analyzed. According to the obstetric complications, the patients were divided into four groups: 34 cases, 22 cases of placenta previa, 28 cases of premature rupture of membranes and 10 cases of twin. All patients were treated with rituximab before and after treatment, respectively, the average incidence of each group and average delivery time statistics. Results The average heart rate of patients on admission was (83.43 ± 3.89) and that of ritodrine (108.92 ± 7.68). The difference was statistically significant before and after treatment (P <0.05), the average time of onset was (34.27 ± 1.87) weeks, the average delivery time after treatment was (38.34 ± 4.92) weeks, with significant difference before and after treatment (P <0.05). Conclusion Rituximab treatment of pregnant women increased heart rate, rituximab for the treatment of early pregnant women with good clinical results.